Simulations Plus cuts FY25 revenue view to $76M-$80M from $90M-$93M

Consensus $90.25M. “To better position the Company for long-term alignment with our clients, we recently announced a strategic reorganization-transitioning from a business unit structure to a functionally driven operating model. We also made key leadership appointments to enhance client engagement and elevate our sales and marketing capabilities. These actions mark the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies across teams, and concentrating our resources on the most promising growth opportunities. We believe the new organizational structure will also foster greater collaboration through centralized product and technology development, contributing to accelerated delivery of software enhancements, platform integration, and AI advancements. Finally, these changes are expected to improve operational efficiency and better position us for sustainable and profitable long-term growth. Looking ahead, we remain optimistic about the future of predictive analytics in biosimulation and clinical operations. These capabilities are essential to helping our clients achieve greater efficiency and success, and we are proud to be a long-standing partner and innovation leader in this space,” concluded O’Connor.